Clinical states of cirrhosis and competing risks

Journal of Hepatology

Volumn 68, Issue 3, 2018, Pages 563-576

  D'Amico, Gennaro ^a   Morabito, Alberto ^b   D'Amico, Mario ^c   Pasta, Linda ^a   Malizia, Giuseppe ^a   Rebora, Paola ^d   Valsecchi, Maria Grazia ^d  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Cirrhosis; Clinical course of cirrhosis; Clinical states of cirrhosis; Competing risks; Cumulative incidence function; Multistate models for cirrhosis; Portal hypertension

Indexed keywords

CLINICAL RESEARCH; DISEASE COURSE; HEALTH STATUS; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL; REVIEW; RISK; COMPLICATION; DISEASE EXACERBATION; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT;

DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS; PROGNOSIS; RISK ASSESSMENT;

EID: 85040606459     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.10.020     Document Type: Review

References (143)

1. Tsochatzis, E.A., Bosch, J., Burroughs, A.K., Liver cirrhosis. Lancet 383 (2014), 1749–1761.
2. Saunders, J.B., Walters, J.R.F., Davies, P., Paton, A., A 20-year prospective study of cirrhosis. Brit Med J 282 (1981), 263–266.
3. Ginés, P., Quintero, E., Arroyo, V., Terés, J., Bruguera, M., Rimola, A., et al. Compensated cirrhosis. Natural history and prognostic factors. Hepatology 7 (1987), 122–128.
4. D'Amico, G., Garcia-Tsao, G., Pagliaro, L., Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 44 (2006), 217–231.
5. Garcia-Tsao, G., Friedman, S., Iredale, J., Pinzani, M., Now there are many stages where before there was one: in search of pathophysiological classification of cirrhosis. Hepatology 51 (2010), 1445–1449.
6. Bruno, S., Zuin, M., Crosignani, A., Rossi, S., Zadra, F., Roffi, L., et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long term prospective study. Am J Gastroenterol 104 (2009), 1147–1158.
7. Vilar Gomez, E., Sanchez Rodriguez, Y., Calzadilla Bertot, L., Torres Gonzalez, A., Martinez Perez, Y., Arus Soler, A., et al. The matural history of compensated HCV-related cirrhosis: a prospective long-term study. J Hepatol 58 (2013), 434–444.
8. Jepsen, P., Ott, P., Andersen, P.K., Sorensen, H.T., Vilstrup, H., The clinical course of alcoholic liver cirrhosis: A Danish population-based cohort study. Hepatology 51 (2010), 1675–1682.
9. Zipprich, A., Garcia-Tsao, G., Rogowsky, S., Fleig, W.E., Seufferlein, T., Dollinger, M.M., Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liv Int, 2012, 1407–1414.
10. D'Amico, G., Pasta, L., Morabito, A., D'Amico, M., Caltagirone, M., Malizia, G., et al. Competing risks and prognostic stages in cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 39 (2014), 1180–1193.
11. Groszmann, R.J., Garcia-Tsao, G., Bosch, J., Grace, N.D., Burroughs, A.K., Planas, R., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353 (2005), 2254–2261.
12. Ripoll, C., Groszmann, R., Garcia-Tsao, G., Grace, N., Burroughs, A., Planas, R., et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133 (2007), 481–488.
13. Villanueva, C., Albillos, A., Jenescà J., Abraldes, J., Calleca, J.L., Aracil, C., et al. Development of hyperdinamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension. Hepatology 63 (2016), 197–206.
14. Bernardi, M., Moreau, R., Angeli, P., Schnabl, B., Arroyo, V., Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilatation to systemic inflammation hypothesis. J Hepatol 63 (2015), 1272–1284.
15. Kutami, R.G.N., Wanless, I.R., Sniderman, K., et al. The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with wedged hepatic vein pressure and clinical features. Hepatology, 32, 2000, 407A.
16. Nagula, S., Jain, D., Groszmann, R.J., Garcia-Tsao, G., Histological–hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. J Hepatol 44 (2006), 111–117.
17. Sethasine, S., Jain, D., Groszmann, R., Garcia-Tsao, R., Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology 55 (2012), 1146–1153.
18. Kim, M.Y., Cho, M.Y., Baik, S.K., Park, H.J., Jeon, H.K., Im, C.K., et al. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 55 (2011), 1004–1009.
19. Rastogi, A., Maiwall, R., Bihari, C., Ahuja, A., Kumar, A., Singh, T., et al. Cirrhosis histology and Laennec staging system correlate with high portal pressure. Histopathology 62 (2013), 731–741.
20. Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958), 457–481.
21. Kalbfleisch, J.D., Prentice, R.L., The statistical analysis of failure time data. 2002, John Wiley and Sons, New York.
22. Andersen, P.K., Geskus, R.B., de Witte, T., Putter, H., Competing risks in epidemiology: Possibilities and pitfalls. Int J Epidemiol 41 (2012), 861–870.
23. Pintile, M., Competing risks. A practical perspective. 2006, John Wiley & Sons, Chichester.
24. Andersen, P.K., Keiding, N., Multistate models for event history analysis. Stat Methods Med Res 11 (2002), 91–115.
25. Iwakiri, Y., Groszmann, R.J., The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43 (2006), S121–S131.
26. Abraldes, J.G., Iwakiri, Y., Loureiro-Silva, M., Haq, O., Sessa, W.C., Groszmann, R.J., Mild increases in portal pressure up-regulate VEGF and eNOS in the intestinal microcirculation leading to hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 290 (2006), G980–G987.
27. Møller, S., Hobolth, L., Winkler, C., Bendtsen, F., Christensen, E., Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 60 (2011), 1254–1259.
28. Calvaruso, V., Burroughs, A.K., Standish, R., Manousou, P., Grillo, F., Leandro, G., et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49 (2009), 1236–1244.
29. De Franchis, R., Updating consensus in portal hypertension. Report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 33 (2000), 846–852.
30. Merli, M., Nicolini, G., Angeloni, S., Rinaldi, V., De Santis, A., Merkel, C., et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 38 (2003), 266–272.
31. D'Amico, G., Pasta, L., Madonia, S., Tarantino, I.G., Mancuso, A., Malizia, G., et al. The incidence of esophageal varices in cirrhosis. Gastroenterology, 120, 2001, A2.
32. Zoli, M., Merkel, C., Magalotti, D., Gueli, C., Grimaldi, M., Gatta, A., et al. Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am J Gastroenterol 95 (2000), 503–508.
33. The North Italian Endoscopic Club for the study and treatment of esophageal varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective study. N Engl J Med 319 (1988), 983–989.
34. Reverter, E., Tandon, P., Augustin, S., Turon, F., Casu, S., Bastiampillai, R., et al. A MELD-Based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology 146 (2014), 412–419.
35. D'Amico, G., De Franchis, R., Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 38 (2003), 599–612.
36. Graham, D.Y., Smith, J.L., The course of patients after variceal hemorrhage. Gastroenterology 80 (1981), 800–809.
37. Bernard, B., Lebrec, D., Mathurin, P., Opolon, P., Poynard, T., Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 25 (1997), 63–70.
38. D'Amico, G., Pagliaro, L., Bosch, J., Pharmacological treatment of portal hypertrnsion. An evidence based Approach. Semin Liver Dis 19 (1999), 475–504.
39. Gonzalez, R., Zamora, J., Gomez-Camarero, J., Molinero, L.M., Banares, R., Albillos, A., Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 149 (2008), 109–122.
40. Albillos, A., Zamora, J., Martinez, J., Arroyo, D., Ahmad, I., De la Pena, J., et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. Hepatology 66 (2017), 1219–1231.
41. Garcia-Pagan, J.C., Caca, K., Bureau, C., Laleman, W., Appenrodt, B., Luca, A., et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 362 (2010), 2370–2379.
42. Planas, R., Montoliu, S., Ballestè B., Rivera, M., Mireia, M., Masnou, H., et al. Natural History of patients hospitalized for management of cirrhotic ascites. Clin Gastro Hepatol 4 (2006), 1385–1394.
43. Salerno, F., Cammà C., Enea, M., Rossle, M., Wong, F., Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133 (2007), 825–834.
44. Bureau, C., Thabut, D., Oberti, F., Dharancy, S., Carbonell, N., Bouvier, A., et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 152 (2017), 157–163.
45. Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K.D., et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60 (2014), 715–735.
46. Thomsen, K.L., Macnaughtan, J., Tritto, G., Mookerjee, R.P., Jalan, R., Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. PLoS One, 11, 2016, e0146076.
47. Bajaj, J.S., Cordoba, J., Mullen, K.D., Amodio, P., Shawcross, D.L., Butterworth, R.F., et al. Review article: the design of clinical trials in hepatic encephalopathy–an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 33 (2011), 739–747.
48. Patidar, K.R., Thacker, L.R., Wade, J.B., Sterling, R.K., Sanyal, A.J., Siddiqu, M.S., et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol 109 (2014), 1757–1763.
49. Piano, S., Rosi, S., Maresio, G., Fasolato, S., Cavallin, M., Romano, A., et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 59 (2013), 482–489.
50. Fagundes, C., Barreto, R., Guevara, M., Garcia, E., Solà E., Rodríguez, E., et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol 59 (2013), 474–481.
51. Angeli, P., Ginès, P., Wong, F., Bernardi, M., Boyer, T.D., Gerbes, A., et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol 62 (2015), 968–974.
52. Tsien, C.D., Rabie, R., Wong, F., Acute kidney injury in decompensated cirrhosis. Gut 62 (2013), 131–137.
53. Fede, G., D'Amico, G., Arvaniti, V., Tsochatzis, E., Germani, G., Georgiadis, D., et al. Renal Failure and cirrhosis: a Systematic review of mortality and prognosis. J Hepatol 56 (2012), 810–818.
54. Salerno, F., Cazzaniga, M., Merli, M., Spinzi, G., Saibeni, S., Salmi, S., et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice. J Hepatol 55 (2011), 1241–1248.
55. Wiest, R., Lawson, M., Geuking, M., Pathological bacterial translocation in liver cirrhosis. J Hepatol 60 (2014), 197–209.
56. Dionigi E, Garcovich M, Borzio M, Leandro G, Majumdar A, Tsami A et al. Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. AJG 2017 e-published ahed of print. doi: 10.1038/ajg.2017.19.
57. Borzio, M., Salerno, F., Piantoni, L., Cazzaniga, M., Angeli, P., Bissoli, F., et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 33 (2001), 41–48.
58. Fernandez, J., Navasa, M., Gomez, J., Colmenero, J., Vila, J., Arroyo, V., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 35 (2002), 140–148.
59. Fernandez, J., Acevedo, J., Castro, M., Garcia, O., Rodrıguez de Lope, C., Roca, D., et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 55 (2012), 1551–1561.
60. Bajaj, J.S., O'Leary, J.G., Wong, F., Reddy, K.R., Kamath, P.S., Bacterial infections in end-stage liver disease: current challenges and future directions. Gut 61 (2012), 1219–1225.
61. Piano, S., Morando, F., Carretta, G., Tonon, N., Vettore, E., Rosi, S., et al. Predictors of early readmission in patients with cirrhosis after the resolution of bacterial infections. Am J Gastroenterol, 2017, 10.1038/ajg.2017.253.
62. Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. J Hepatol 60 (2014), 1310–1324.
63. Arvaniti, V., D'Amico, G., Fede, G., Manosou, P., Tsochatzis, E., Pleguezuelo, M., et al. Infections in patients with cirrhosis increases mortality four-fold and should be used in determining prognosis. Gastroenterology 139 (2010), 1246–1256.
64. Nahon, P., Lescat, M., Layese, R., Bourcier, V., Talmat, N., Allam, S., et al. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut 66 (2017), 330–341.
65. Zhao, C., Nguyen, M.H., Hepatocellular carcinoma screening and surveillance. practice guidelines and real-life practice. J Clin Gastroenterol 50 (2016), 120–133.
66. Fattovich, G., Stroffolini, T., Zagni, I., Donato, F., Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004), s35–s50.
67. Ioannou, G., Splan, M., Weiss, N., McDonald, G., Beretta, L., Lee, S., Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 5 (2007), 938–945.
68. Lok, A.S., Seeff, L.B., Morgan, T.R., Di Bisceglie, A.M., Sterling, R.K., Curto, T.M., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136 (2009), 138–148.
69. Giannini, E.G., Risso, D., Testa, R., Trevisani, F., Di Nolfo, M.A., Del Poggio, P., et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastro Hepatol 4 (2006), 1378–1384.
70. Ripoll, C., Groszmann, R.J., Garcia-Tsao, G., Bosch, J., Grace, N., Burroughs, A., et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 50 (2009), 923–928.
71. Shim, J.J., Oh, C.H., Kim, J.W., Lee, C.H., Kim, B.H., Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. Scand J Gastroenterol, 2017, 10.1080/00365521.2017.1335773.
72. Giannini, E.G., Farinati, F., Ciccarese, F., Pecorelli, A., Rapaccini, G.L., Di Marco, M., et al. Prognosis of untreated hepatocellular carcinoma. Hepatology 61 (2015), 184–190.
73. Llovet, J.M., Bru, C., Bruix, J., Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999), 329–338.
74. Liu, P.H., Hsu, C.Y., Hsia, C.Y., Lee, Y.H., Su, C.W., Huang, S.C., et al. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol 64 (2016), 601–608.
75. Moreau, R., Jalan, R., Gines, P., Pavesi, M., Angeli, P., Cordoba, J., Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144 (2013), 1426–1437.
76. Arroyo, V., Jalan, R., Acute-on-chronic liver failure: definition, diagnosis and clinical characteristics. Semin Liver Dis 36 (2016), 109–116.
77. Bajaj, J.S., O'Leary, J.G., Reddy, R., Wong, F., Biggins, S.W., Patton, H., et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 60 (2014), 250–256.
78. Hernaez, R., Solà E., Moreau, R., Ginès, P., Acute-on-chronic liver failure: an update. Gut 66 (2017), 541–553.
79. Claria, J., Stauber, E.R., Coenraad, M.J., Moreau, R., Jalan, R., Pavesi, M., Systemic inflammation in decompensated cirrhosis. Characterization and role in acute-on-chronic liver failure. Hepatology 64 (2016), 1249–1264.
80. Solé C., Solà E., Morales-Ruiz, M., Fernandez, G., Huelin, P., Graupera, I., et al. Characterization of inflammatory response in acute-on-chronic liver failure and relationship with prognosis. Sci Rep, 6, 2016, 32341.
81. Moreau, R., The pathogenesis of ACLF. The inflammatory response and immune function. Semin Liver Dis 36 (2016), 133–140.
82. Claria, J., Arroyo, V., Moreau, R., The acute-on-chronic liver failure syndrome, or when the innate immune system goes astray. J Immunol 197 (2016), 3755–3761.
83. Shi, Y., Yang, Y., Hu, Y., Wu, W., Yang, Q., Zheng, M., et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 62 (2015), 232–242.
84. Solà E., Fernandez, J., Gines, P., Acute-on chronic liver failure: the role of precipitating illness. Semin Liver Dis 36 (2016), 117–122.
85. Fernandez, J., Acevedo, J., Weist, R., Gustot, T., Amoros, A., Deulofeu, C., et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut, 2017, 10.1136/gutjnl-2017-314240.
86. Albillos, A., Lario, M., Alvarez-Mon, M., Cirrhosis associated imuune dysfunction: distinctive features and clinical relevance. J Hepatol 61 (2014), 1385–1396.
87. Kubes, P., Mehal, W.Z., Sterile inflammation in the liver. Gastroenterology 143 (2012), 1158–1172.
88. Gustot, T., Fernandez, J., Garcia, E., Morando, F., Caraceni, P., Alessandria, C., et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 62 (2015), 243–252.
89. Jalan, R., Pavesi, M., Saliba, F., Amoros, A., Moreau, R., Jines, P., et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 61 (2014), 1038–1047.
90. Jalan, R., Pavesi, M., Saliba, F., Amoros, A., Fernandez, J., Holland-Fisher, P., et al. The CLIF consortium acute decompensation score (CLIF-C Ads) for prognosis of hospitalized cirrhotic patients without acute-on-cronich liver failure. J Hepatol 62 (2015), 831–840.
91. Li, H., Chen, L.Y., Zhang, N.N., Li, S.T., Zeng, B., Pavesi, M., et al. Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B. Sci Rep, 6, 2016, 25487, 10.1038/srep25487.
92. Piano, S., Tonon, M., Vettore, E., Stanco, M., Pilutti, C., Romano, A., et al. Incidence, predictors and outcome of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol 67 (2017), 1177–1184.
93. Bedossa, P., Garcia-Tsao, G., Jain, D., Cirrhosis regression and subclassification. Pathology 6 (2013), 295–309.
94. D'Ambrosio, R., Aghemo, A., Rumi, M.G., Ronchi, G., Donato, M.F., Paradis, V., A morphometric and immunoistochemical study to assess the benefit of sustained virological response in hepatitis c virus patients with cirrhosis. Hepatology 56 (2012), 532–543.
95. Vorobioff, J., Groszmann, R., Picabea, E., Gamen, M., Villavicenzcio, R., Bordato, J., et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 111 (1996), 701–709.
96. Berzigotti, A., Albillos, A., Villanueva, C., Genescá J., Ardevol, A., Augustín, S., et al. Effects of an intensive lifestyle intervention program on portal hypertension patients with cirrhosis and obesity: the sportdiet study. Hepatology 65 (2017), 1293–1305.
97. Mandorfer, M., Kozbial, K., Schwabl, P., Freissmuth, C., Schwarzer, R., Stern, R., et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 65 (2016), 692–699.
98. Van der Meer, A., Feld, J., Hofer, H., Almasio, P., Calvaruso, V., Fernandez-Rodriguez, C., et al. Risk of cirrhosis related complications in patients with advanced fibrosis following hepatitis c virus eradication. J Hepatol 66 (2017), 485–493.
99. Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. Survival of patients with HCV cirrhosis and sustained virological response is similar to the general population. J Hepatol 64 (2016), 1217–1223.
100. Reig, M., Marino, Z., Perellò C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected high rate of early tumor recurrence in patients with HCV related HCC undergoing interferon free therapy. J Hepatol 65 (2016), 719–726.
101. Di Marco, V., Calvaruso, V., Ferraro, D., Bavetta, M.G., Cabibbo, G., Conte, E., et al. Effects of eradicating hepatitis c virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 151 (2016), 130–139.
102. Ioannau, G., Green, PK., Berry, K., HCV eradication induced by direct-acting antiviral agents reduce the risk of hepatocellular carcinoma. J Hepatol 68 (2018), 25–32.
103. Varborbitis, I., Papatheodoridis, G.V., The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol 22 (2016), 319–326.
104. De Franchis, R., Baveno VI faculty. Expanding consensus in portal hypertension. Report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 63 (2015), 743–752.
105. European Association for the Study of the Liver. EASL 2017 clinical practice guideline on the management of hepatitis B virus infection. JHepatol 67 (2017), 370–398.
106. Thomsen, B.L., Møller, S., Sørensen, T., Optimized analysis of recurrent bleeding and death in patients with cirrhosis and esophageal varices. Copenhagen Esophageal Varices Sclerotherapy Project. J Hepatol 21 (1994), 367–375.
107. Garcia-Tsao, G., Abraldes, J., Berzigotti, A., Bosch, J., Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis and management: 2016 practice guidance by the American Association for the Study of the Liver. Hepatology 65 (2017), 310–335.
108. Augustin S, Pons M, Santos B, Ventura M, Genescà J. Identifyinf chronic advanced liver disease: when not to start screening for varices and clinically significant portal hypertension. In de Franchis R ed: Portal hypertension VI. Proceeding of the sixth Baveno consensus workshop: stratifying risk and individualizing care. Springer international publishing Switzerland; 2016; 39–50.
109. Berzigotti, A., Seijo, S., Arena, U., Abraldes, J.G., Vizzutti, F., Garcia-Pagan, J.C., et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 144 (2013), 102–111.
110. Abraldes, J.G., Bureau, C., Stefanescu, H., Augustin, S., Ney, M., Blasco, H., et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “anticipate” study. Hepatology 64 (2016), 2173–2184.
111. Berzigotti, Annalisa., Non-invasive evaluation of portal hypertension using ultrasound elastography. J Hepatol 67 (2017), 399–411.
112. D'Amico, G., Morabito, A., Pagliaro, L., Marubini, E., Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31 (1986), 468–475.
113. Ginés, P., Quintero, E., Arroyo, V., Terés, J., Bruguera, M., Rimola, A., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 7 (1987), 122–128.
114. Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., et al. Morbidity and mortality in compensated cirrhosis type c: A retrospective follow-up study of 384 patients. Gastroenterology 112 (1997), 463–472.
115. Hu, K.G., Myron, J., Tong, M.J., The long-term outcomes of patients with compensated hepatitisC virus–related cirrhosis and history of parenteral exposure in the united states. Hepatology 29 (1999), 1311–1316.
116. Benvegnù L., Gios, M., Boccato, S., Alberti, A., Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53 (2004), 744–749.
117. Sangiovanni, A., Prati, G.A., Fasani, P., Ronchi, G., Romeo, R., Manini, M., et al. The natural history of compensated cirrhosis due to hepatitis C virus. A 17-year cohort study of 214 patients. Hepatology 43 (2006), 1303–1310.
118. Fleming, K.M., Aithal, G.P., Card, T.R., West, J., The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther 32 (2010), 1343–1350.
119. Abraldes, J.G., Villanueva, C., Banares, R., Aracil, C., Catalina, M.V., Garcıa-Pagan, J.C., BoschJ. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 48 (2008), 229–236.
120. Gheorghe, L., Iacob, S., Simionov, I., Vadan, R., Gheorghe, C., Iacob, R., et al. Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol 14 (2015), 329–335.
121. Sanyal, A.J., Banas, C., Sargeant, C., Luketic, V.A., Sterling, R.K., Stravitz, R.T., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43 (2006), 682–689.
122. Romanelli, R.G., La Villa, G., Barletta, G., Vizzutti, F., Lanini, F., Arena, U., et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial. World J Gastroenterol 12 (2006), 1403–1407.
123. Planas, R., Balleste, B., Alvarez, M.A., Rivera, M., Montoliu, S., Galeras, J.A., et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatoly 40 (2004), 823–830.
124. Solà R., Alvarez, M.A., Ballesté B., Montoliu, S., Rivera, M., Mireia, M., et al. Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients. Liver Int 26 (2006), 62–72.
125. Fernàndez-Esparrach, G., Sànchez-Fueyo, A., Ginés, P., Uriz, J., Quintò L., Ventura, P.J., et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 34 (2001), 46–52.
126. Bruno, S., Saibeni, S., Bagnardi, V., Vandelli, C., De Luca, M., Felder, M., et al. Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy. Am J Gastroenterol 108 (2013), 1112–1122.
127. Moller, S., Bendtsen, F., Complications of cirrhosis. A 50-yrs flashback. Scand J Gastroenterol 50 (2015), 763–780.
128. Møller, S., Hobolth, L., Winkler, C., Bendtsen, F., Christensen, E., Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut, 60, 2011, 1254e1259.
129. Møller, S., Henriksen, J.H., Cardiovascular complications of cirrhosis. Gut, 57, 2008, 268e78.
130. Krag, A., Bendtsen, F., Henriksen, H., Møller, S., Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 59 (2010), 105–110.
131. Ginès, P., Schrier, R.W., Renal Failure in Cirrhosis. N Engl J Med 361 (2009), 1279–1290.
132. Nadim, M.K., Durand, F., Kellum, J.A., Levitsky, J., O'Leary, J.G., Carvellas, C.J., et al. Management of the critically ill patient with cirrhosis. A multidisciplinary perspective. J Hepatol 64 (2016), 717–735.
133. Durand, F., Nadim, M.K., Management of acute-on-chronic liver failure. Semin Liv Dis 36 (2016), 141–152).
134. Jalan, R., Novel approach and therapeutics in acute on chronic liver failure. Liver Transpl 22 (2016), 14–19.
135. Jepsen, P., Wilstrup, H., Andersen, P.K., The clinical course of cirrhosis. The importance of multistate models and competing risks analysis. Hepatology 62 (2015), 292–302.
136. Rothman, K.J., Epidemiology: An Introduction. 2002, University Press, New York: Oxford.
137. Putter, H., Fiocco, M., Geskus, R.B., Tutorial in biostatistics: competing risks and multi-state models. Statist Med 26 (2007), 2389–2430.
138. Cox, D.R., Regression models and life-tables (with discussion). J R Statist Soc B 34 (1972), 187–220.
139. Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of competing risk. J Am Stat Ass 94 (1999), 496–509.
140. Wolbers, M., Koller, M.T., Wittenam, J.C.M., Steyerberg, E.W., Prognostic models with competing risks. Methods and application to coronary risk prediction. Epidemiol 20 (2009), 555–561.
141. D'Amico, G., Politi, F., Morabito, A., D'Antoni, A., Guerrera, D., Giannuoli, G., et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, Randomized pragmatic trial. Hepatology 28 (1998), 1206–1214.
142. Schoenfeld, D.A., Sample-size formula for the proportional-hazards regression model. Biometrics 39 (1983), 499–503.
143. BC Tai, ZJ Chen, D Machin. Estimating sample size in the presence of competing risks – Cause-specific hazard or cumulative incidence approach? Stat Methods in Med Res First published date: December-27-2015 DOI 10.1177/0962280215623107.